US WorldMeds, LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From US WorldMeds, LLC
2022 Deal-Making Snapshot: One Big Deal Didn’t Change The Downward Trends
Even with Amgen’s $27.8bn acquisition of Horizon in mid-December, biopharma M&A volume, total value and average deal value all dropped substantially from 2021.
FTC Rebukes Supernus Efforts To Block Sales Of Injector Pen For Use With Generic Apokyn
Agency refutes Supernus’ defense that Sage’s generic drug cartridges are ‘free-riding’ on the supply of the injector pen for its branded product. Company’s alleged exclusionary contract with pen distributor and pressure on specialty pharmacies not to provide the generic involve important antitrust issues, FTC tells court.
Asia Deal Watch: Eisai Advances Portfolio Focus With Divestiture Of Two Products To DKSH
Plus deals involving Dong-A/Polifarma, Intas/Syna, Kissei/Synmosa, Ono/Memo, Takeda/Shionogi, Fosun/Lilly and JW Therapeutics/2seventy bio.
Keeping Track: Furoscix, SPN-830 Show Difficulties Of Drug-Device Combinations
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Sloan Pharma S.a.r.l
- Solstice Neurosciences
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.